Recently, Mori et al. (2014), in an open-labelled, prospective randomized study, evaluated the effects of 50 mg/day of sitagliptin (versus other oral glucose-lowering agents) on urinary albumin excretion in T2DM patients, during 6 weeks. Here, ALB is linked to type 2 diabetes mellitus.